Anchor Pointe Wealth Management’s AbbVie ABBV Stock Holding History

Anchor Pointe Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$210K	Buy	+1,191	New	+$219K	0.27%	81

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Anchor Pointe Wealth Management's ABBV Position: Q4 2024 in Review

Anchor Pointe Wealth Management opened a new position in AbbVie (ABBV) in Q4 2024: 1,191 shares worth $210K. The stake represents 0.27% of the portfolio and ranks #81 among its holdings.

3,750 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

Anchor Pointe Wealth Management held 1,191 shares of AbbVie worth $210K as of Q4 2024.
AbbVie was a new Anchor Pointe Wealth Management position in Q4 2024.
AbbVie made up 0.27% of Anchor Pointe Wealth Management's portfolio in Q4 2024, its #81 holding.
3,750 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Anchor Pointe Wealth Management's 13F filing for Q4 2024, filed 11 Mar 2025.